Blueprint Medicines Corporation was acquired by Sanofi in July 2025. BPMC no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Sanofi, and their dates may not have been updated since.
Clinical trial readout dates for Blueprint Medicines Corporation, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2026.